SLC15A2

Solute carrier family 15 member 2 · Q16348 · SLC15A2 on Sugi Atlas →

18,872 patent compounds predicted against SLC15A2, 12,626 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Loracarbef Anhydrous (SCHEMBL34153)	0.66	4/20
Loracarbef Anhydrous (SCHEMBL235140)	0.66	4/20
Loracarbef Anhydrous (SCHEMBL34152)	0.65	4/20
Loracarbef Anhydrous (SCHEMBL537031)	0.65	4/20
Loracarbef Anhydrous (SCHEMBL1229813)	0.65	4/20
Cephalexin Anhydrous (SCHEMBL2961)	1.00	3/20
Cefaclor Anhydrous (SCHEMBL33540)	1.00	3/20
Cefaclor Anhydrous (SCHEMBL49912)	1.00	3/20
Cefadroxil (SCHEMBL151320)	1.00	3/20
Cefadroxil (SCHEMBL524155)	1.00	3/20
Cefaclor Anhydrous (SCHEMBL1006419)	1.00	3/20
Cefadroxil (SCHEMBL33620)	0.98	3/20
Cefadroxil (SCHEMBL146152)	0.98	3/20
Cefaclor Anhydrous (SCHEMBL33539)	0.98	3/20
Cephalexin Anhydrous (SCHEMBL40988)	0.98	3/20
Cephalexin Anhydrous (SCHEMBL41911)	0.98	3/20
Cefaclor Anhydrous (SCHEMBL956758)	0.98	3/20
Cephalexin Anhydrous (SCHEMBL1443389)	0.98	3/20
Cephalexin Anhydrous (SCHEMBL582342)	0.96	3/20
Cefadroxil (SCHEMBL296698)	0.94	3/20

Clinical trials — most relevant to SLC15A2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Age on the Renal Clearance of Adefovir	PHASE4	WITHDRAWN
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)	PHASE2	COMPLETED
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy	PHASE2	ACTIVE_NOT_RECRUITING
Intrathecal Gene Therapy For SLC13A5 Citrate Transporter Disorder	PHASE1/PHASE2	NOT_YET_RECRUITING
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia	PHASE1/PHASE2	RECRUITING
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia	PHASE1/PHASE2	COMPLETED
Effect of, OAT3, on the Renal Secretion of Cefotaxime	PHASE1	COMPLETED
THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC	PHASE1	COMPLETED
Genotype Stratified Pharmacokinetic Study of Montelukast	PHASE1	COMPLETED
Statin Therapy to Improve Medication Adherence	PHASE1	COMPLETED
Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer	EARLY_PHASE1	UNKNOWN
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters	EARLY_PHASE1	COMPLETED
SLC13A5 Deficiency Natural History Study - Remote Only	nan	ENROLLING_BY_INVITATION
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy	nan	COMPLETED
Understanding Methotrexate Induced Gastrointestinal Intolerance in Juvenile Idiopathic Arthritis and Childhood Leukemia	nan	COMPLETED
Oxalate and Citrate in Humans - Response to Citrate	nan	RECRUITING
Hyperlactacidemia in Major Abdominal Surgery and Monocarboxylate Receptors	nan	UNKNOWN
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs	nan	COMPLETED
Bile Acid Effects in Fetal Arrhythmia Study	nan	UNKNOWN
Impact of Genetics on Metformin Pharmacokinetics	nan	COMPLETED
ADPKD Alterations in Hepatic Transporter Function	nan	COMPLETED
SLC13A5 Deficiency Natural History Study - United States Only	nan	ENROLLING_BY_INVITATION
Genetically Guided Statin Therapy	nan	COMPLETED
Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides	nan	COMPLETED
Characterization of Breg Cells	nan	COMPLETED
Cancer and Hearing Loss Related in Children	nan	COMPLETED
Evaluation of HPGD and SCLO2A1 Expression in Clear Cell Renal Cell Carcinoma Patients	nan	COMPLETED
Effect of SLC01B1 (rs4149956) Polymorphism on the Efficacy and Tolerability of Atorvastatin in Pakistani Population	nan	COMPLETED
Choroid Plexus Dysfunction in Neurological Diseases	nan	RECRUITING
Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a SLC15A2 binder may also engage these)

Protein	Name	Similarity
P46029	—	1.000	P46029 →
Q9ES07	—	1.000	Q9ES07 →
Q63424	—	1.000	Q63424 →
P36836	—	0.996	P36836 →
B0S6T2	—	0.993	B0S6T2 →
P51574	—	0.991	P51574 →
SLC15A1	Solute carrier family 15 member 1	0.990	landscape →
Q8WMX5	—	0.988	Q8WMX5 →
Q9JIP7	—	0.987	Q9JIP7 →
P91679	—	0.986	P91679 →
Q21219	—	0.981	Q21219 →
O01840	—	0.981	O01840 →
Q17758	—	0.980	Q17758 →
SLC33A1	Acetyl-coenzyme A transporter 1	0.980	landscape →
O23596	—	0.979	O23596 →
Q6AYY8	—	0.979	Q6AYY8 →
Q99J27	—	0.978	Q99J27 →
Q9SB41	—	0.976	Q9SB41 →
GRM5	Metabotropic glutamate receptor 5	0.976	landscape →
GRM1	Metabotropic glutamate receptor 1	0.975	landscape →
P60815	—	0.975	P60815 →
Q7TSF2	—	0.975	Q7TSF2 →
Q5RFF0	—	0.975	Q5RFF0 →
Q27960	—	0.975	Q27960 →
P31424	—	0.975	P31424 →
A0JNI9	—	0.974	A0JNI9 →
P46720	—	0.974	P46720 →
P53793	—	0.974	P53793 →
SLCO4C1	Solute carrier organic anion transporter family member 4C1	0.974	landscape →
Q8NDX2	—	0.974	Q8NDX2 →